COMPASS Pathways
Mental health care company pioneering the development of psilocybin therapy COMP360 for treatment-resistant depression and other mental health conditions, with FDA breakthrough therapy designation.
Notes
COMPASS Pathways (NASDAQ: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is developing COMP360, a proprietary formulation of synthetic psilocybin being studied in clinical trials for treatment-resistant depression (TRD).
COMP360 psilocybin therapy received FDA Breakthrough Therapy designation in 2018, and the company is conducting one of the largest clinical programs with psilocybin in the world. The therapy is administered in conjunction with psychological support.
Team
- Kabir Nath - Chief Executive Officer (as of 2024)
- LinkedIn: linkedin.com/in/kabirnath
- George Goldsmith - Co-founder & Executive Chairman
- LinkedIn: linkedin.com/in/georgegoldsmith
- Ekaterina Malievskaia, M.D. - Co-founder & Chief Innovation Officer
Additional Research Findings
- NASDAQ: CMPS (publicly traded, IPO 2020)
- COMP360 psilocybin therapy for treatment-resistant depression
- FDA Breakthrough Therapy designation (2018)
- Phase 3 clinical trials ongoing
- Proprietary synthetic psilocybin formulation
- Therapy includes psychological support component
- Headquarters in London, UK
- One of the largest psilocybin clinical programs globally
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| OMX Ventures | San Francisco, California, USA | biotech-focused | seedseries-a | 23 |